Professional Documents
Culture Documents
notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
Contents
1.
1.1 1.2 1.3 1.4
Executive Summary
What This Report Covers Multiple Myeloma: World Drug Market Overview 2013-2023 Chapter Outlines Research and Analysis Methods
www.visiongain.com
Contents
3.4 The World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass: Grouped Revenue Forecasts, 2013-2023 3.5 Immunomodulators for Multiple Myeloma: Dominating the Market Throughout the Forecast Period 3.5.1 Immunomodulators: Revenue Forecast 2013-2023 3.6 Proteasome Inhibitors: A Cornerstone in Multiple Myeloma Drug Treatment 3.6.1 Proteasome Inhibitors: Revenue Forecast 2013-2023 3.7 Monoclonal Antibodies: Market Launch Anticipated in 2015 3.7.1 Monoclonal Antibodies: Revenue Forecast 2013-2023 3.8 Kinase Inhibitors: A Class of Advanced Cancer Medications 3.8.1 Kinase Inhibitors: Revenue Forecast 2013-2023 3.9 Summary: Growth of the Multiple Myeloma Drug Treatment Market, 2013-2023
Revenue Forecasts, 2013-2023 4.4 The US Will Continue to Dominate the Multiple Myeloma Drug Treatment Market from
2013-2023 4.5 The EU5 Countries 4.5.1 Germany: The Largest EU5 Market Will Have the Lowest Levels of Growth 4.5.2 France: Steadily Decreasing Market Share 4.5.3 Italy: High Growth Between 2013 and 2016
www.visiongain.com
Contents
4.5.4 The UK: Strongest Growth of the EU5 from 2018-2023 4.5.5 Spain: The Smallest Market of the EU5 4.6 4.7 4.8 4.9 4.10 Japan: Delays in Regulatory Approval China: Pursuing Domestic Oncology R&D Brazil: Governmental Healthcare Investments Support Growth Russia: Poor Treatment Outcomes Mean Demand for More-Effective Therapy is High India: A Strong Domestic Drug Industry Limits Market Share
www.visiongain.com
Contents
5.7.2 Zometa: Revenue Forecast, 2013-2023 5.8 Kyprolis: The 2nd Generation Proteasome Inhibitor Will Capture a Large Market Share 5.8.1 The Driving and Restraining Factors for Kyprolis 5.8.2 Kyprolis: Revenue Forecast, 2013-2023 5.9 Pomalyst: Celgenes 3rd Immunomodulator, But Will it Supersede its Predecessors? 5.9.1 Driving and Restraining Factors for Pomalyst 5.9.2 Pomalyst: Revenue Forecast 2013-2023 5.10 Promising Drugs in the R&D Pipeline Elotuzumab: The 1st Monoclonal Antibody For MM? Elotuzumab: Driving and Restraining Forces Elotuzumab: Revenue Forecast, 2013-2023
5.10.1
MLN9708: A Game Changing Proteasome Inhibitor? MLN9708: Driving and Restraining Factors MLN9708: Revenue Forecast, 2013-2023
Panobinostat: A First-in-Class Therapy Panobinostat: Driving and Restraining Factors Panobinostat: Revenue Forecast, 2013-2023
Aplidin: A Marine-Derived Compound for the Treatment of Multiple Myeloma Aplidin: Driving and Restraining Factors Aplidin: Revenue Forecast, 2013-2023
www.visiongain.com
Contents
6.1.1.1 6.1.1.2 6.1.1.3 6.1.1.4 6.1.1.5 Novartis Panobinostat AB Sciences Masitinib Millennium Pharmaceuticals MLN9708 (ixazomib) PharmaMars Aplidin Otsuka America Pharmaceuticals Busulfex
6.1.2 Candidates in Phase II Development: An Abundance of Kinase Inhibitors 6.1.2.1 6.1.2.2 6.1.2.3 6.1.2.4 6.1.2.5 6.1.2.6 6.1.2.7 6.1.2.8 6.1.2.9 6.1.2.10 6.1.2.11 6.1.2.12 Oncopeptides Melflufen Mercks Dinaciclib Astra Zenecas Selumetinib Pharmacyclics Ibrutinib Geron Corporations Imetelstat Celgenes Istodax Bristol-Myers Squibbs Dasatinib Cephalons Treanda Pfizers Torisel Novartis Everolimus Millennium Pharmaceuticals MLN8237 Bayer and Onyx Pharmaceuticals Nexavar
6.1.3 Candidates in Phase I Development 6.1.3.1 GlaxoSmithKlines GSK2110183 (afuresertib): Development Apparently
Suspended 6.1.3.2 6.1.3.3 6.1.3.4 6.1.3.5 Array BioPharmas Arry-520 Arno Therapeutics AR-42 EntreMeds ENMD-2076 Genentechs Erivedge
www.visiongain.com
Contents
6.1.3.6 6.1.3.7 6.2 Allos Therapeutics Folotyn Synta Pharmaceuticals Ganetespib The Biologic Drug Pipeline: Monoclonal Antibodies Dominate 6.2.1 Three Monoclonal Antibodies Dominate the Phase III Developmental Pipeline 6.2.1.1 Elotuzumab Being Developed Under a Collaboration Between Bristol-Myers
Squibb and AbbVie 6.2.1.2 6.2.1.3 Amgens Xgeva: Could it Supersede Zometa? Janssen Biotech and Genmabs Daratumumab
6.2.2 Candidates in Phase II Development 6.2.2.1 6.2.2.2 6.2.2.3 6.2.2.4 6.2.2.5 6.2.2.6 6.2.2.7 6.2.2.8 6.2.2.9 6.2.2.10 Novartis HCD122 (Lucatumumab): Development Appears to Have Stalled Senesco Technologies SNS01-T Glikniks GL-0817 Celldex Therapeutics CDX-1401 Janssens Siltuximab Roches Avastin GlaxoSmithKlines Bexxar Novartis BHQ880 Cell Genesys GVAX Oncovirs Hiltonol
6.2.3 Candidates in Phase I Development 6.2.3.1 6.2.3.2 6.2.3.3 6.2.3.4 6.2.3.5 Genentechs DFRF4539A ImmunoGens Lorvotuzumab Mertansine Eli Lillys Tabalumab Genentechs MFGR1877S Oncolytics Reolysin
www.visiongain.com
Contents
6.3 Future Epigenetics-Based Treatments
7. The Leading Companies of the Multiple Myeloma Drug Treatment Market, 2013
7.1 7.2 7.3 7.4 7.5 7.6 7.7 The Leading Companies in 2012 Celgene Corporation is the Market Leader Johnson & Johnson: Proteasome and MAb Leader Takeda: A Strong Portfolio Through Subsidiary Millennium Pharmaceuticals Novartis: A Small Market Share in 2012, But a Well-Stocked Pipeline Bristol-Myers Squibb: Poised for Market Entry Onyx Pharmaceuticals: Now Part of Amgen
2013-2023 8.2.1 Oncology is a Growth Area for Investment, Creating Opportunities in the Market 8.2.2 Will Oncology Remain a Strong Investment for Pharma?
www.visiongain.com
Contents
8.3 Social, Technological, Economic and Political (STEP) Forces Influencing the Multiple Myeloma Drug Industry and Market, 2013-2023 8.3.1 Social: Adherence, Support and Education are Crucial 8.3.2 Technological: Increasing Understanding of Cancer Biology 8.3.3 Economic: Stretched Healthcare Budgets Will Affect that Drug Industry 8.3.4 Political: Broadening and Narrowing of Governmental Healthcare Spending
10.4.1
www.visiongain.com
Contents
10.4.2 10.4.3 The R&D Pipeline is Large and Diverse The Small Patient Population Generates Uncertainty
www.visiongain.com
Contents
List of Tables
Table 1.1 Currency Exchange Rates, Table 2.1 Drugs Indicated for the Treatment of Multiple Myeloma: Brand Name, Generic Name and Therapeutic Class, 2013 Table 3.1 The World Multiple Myeloma Drug Market by Therapeutic Class: Revenue ($m) and Market Share (%), 2012 Table 3.2 World Multiple Myeloma Drug Market: Overall Revenue Forecast ($m), 2013-2023 Table 3.3 The Multiple Myeloma Drug Market by Therapeutic Class: Comparison of Revenue ($m) and Market Share (%), 2018 and 2023 Table 3.4 Multiple Myeloma Drug Market by Therapeutic Subclass: Group Revenue ($m) and Market Share (%) Forecasts, 2013-2023 Table 3.5 Immunomodulators for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 3.6 Proteasome Inhibitors for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 3.7 Monoclonal Antibodies for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 3.8 Kinase Inhibitors for Multiple Myeloma: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.1 The Leading National Markets: Revenue ($m) and Market Share (%), 2012 Table 4.2 The Leading National Markets: Comparison of Revenue ($m) and Market Share (%), 2018 and 2023 Table 4.3 The Leading National Markets: Grouped Revenue Forecasts ($m), 2013-2023 Table 4.4 The US Multiple Myeloma Drug Treatment Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.5 The EU5 Multiple Myeloma Market by Country: Revenue ($m) and Market Share (%) Forecasts, 2013-2023 Table 4.6 The German Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023
www.visiongain.com
Contents
Table 4.7 The French Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.8 The Italian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.9 The UK Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.10 The Spanish Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.11 The Japanese Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.12 The Chinese Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.13 The Brazilian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.14 The Russian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 4.15 The Indian Multiple Myeloma Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.1 The Leading Drugs for Multiple Myeloma: Revenue ($m) and Market Share (%), 2012 Table 5.2 Leading Drugs for MM: Comparison of Revenue ($m) and Market Share (%), 2018 and 2023 Table 5.3 Leading MM Drugs: Grouped Revenue Forecasts ($m), 2013-2023 Table 5.4 Revlimid: Key Facts Table 5.5 Revlimid: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.6 Velcade: Key Facts Table 5.7 Velcade: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.8 Thalomid: Key Facts Table 5.9 Thalomid: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.10 Zometa: Key Facts Table 5.11 Zometa: Revenue ($m) and Market Share (%) Forecast, 2013-2023
www.visiongain.com
Contents
Table 5.12 Kyprolis: Key Facts Table 5.13 Kyprolis: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.14 Pomalyst: Key Facts Table 5.15 Pomalyst: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.16 Elotuzumab: Key Facts Table 5.17 Elotuzumab: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.18 MLN9708: Key Facts Table 5.19 MLN9708: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.20 Panobinostat: Key Facts Table 5.21 Panobinostat: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 5.22 Aplidin: Key Facts Table 5.23 Aplidin: Revenue ($m) and Market Share (%) Forecast, 2013-2023 Table 6.1 Small Molecule Candidates in Phase III Development For MM, 2013 Table 6.2 Small Molecule Candidates in Phase II Development for MM, 2013 Table 6.3 Small Molecule Candidates in Phase I Development for MM, 2013 Table 6.4 Biologic Candidates in Phase III Development for MM, 2013 Table 6.5 Biologic Candidates in Phase II Development for MM, 2013 Table 6.6 Biologic Candidates in Phase I Development for MM, 2013 Table 7.1 The Leading Companies in the MM Drug Market: Revenue ($m) and Market Share (%), 2012 Table 7.2 Celgene: Multiple Myeloma Product Portfolio, 2013 Table 7.3 Johnson & Johnson: Multiple Myeloma Product Portfolio, 2013 Table 7.4 Takeda: Multiple Myeloma Product Portfolio, 2013 Table 7.5 Novartis: Multiple Myeloma Product Portfolio, 2013 Table 7.6 Bristol-Myers Squibb: Multiple Myeloma Product Portfolio, 2013 Table 7.7 Amgen: Multiple Myeloma Product Portfolio, 2013 Table 8.1 Strengths and Weaknesses of the Multiple Myeloma Drug Treatment Market, 2013 Table 8.2 Opportunities and Threats Facing the Multiple Myeloma Drug Treatment Market, 2013-2023
www.visiongain.com
Contents
Table 8.3 The Social, Technological, Economic and Political Factors Influencing the MM Drug Treatment Market, 2013-2023
www.visiongain.com
Contents
List of Figures
Figure 2.1 The Incidence Rate of Multiple Myeloma (per 100,000) by World Region, 2008 Figure 3.1 The World Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%), 2012 Figure 3.2 The World Multiple Myeloma Drug Treatment Market: Revenue Forecast ($m), 20132023 Figure 3.3 The Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%), 2018 Figure 3.4 The Multiple Myeloma Drug Market by Therapeutic Class: Market Share (%), 2023 Figure 3.5 The Multiple Myeloma Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2013-2023 Figure 3.6 Immunomodulators for Multiple Myeloma: Revenue Forecast ($m), 2013-2023 Figure 3.7 Proteasome Inhibitors for Multiple Myeloma: Revenue Forecast ($m), 2013-2023 Figure 3.8 Monoclonal Antibodies for Multiple Myeloma: Revenue Forecast ($m), 2013-2023 Figure 3.9 Kinase Inhibitors for Multiple Myeloma: Revenue Forecast ($m), 2013-2023 Figure 3.10 The Multiple Myeloma Drug Treatment Market: Driving and Restraining Factors, 2013 Figure 4.1 The Leading National Markets: Market Shares (%), 2012 Figure 4.2 The Leading National Markets for Multiple Myeloma: Market Share (%), 2018 Figure 4.3 The Leading National Markets for Multiple Myeloma: Market Share (%), 2023 Figure 4.4 The US Multiple Myeloma Drug Treatment Market: Revenue Forecast ($m), 20132023 Figure 4.5 US: Multiple Myeloma Drug Market Penetration Usage of Revlimid, Velcade and Thalomid in Early Stage of Disease (%), 2011 Figure 4.6 US: Multiple Myeloma Drug Market Penetration Usage of Revlimid, Velcade and Thalomid in Late Stages of Disease (%), 2011 Figure 4.7 The EU5 Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.8 The German Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.9 The French Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.10 The Italian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023
www.visiongain.com
Contents
Figure 4.11 The UK Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.12 The Spanish Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.13 The Japanese Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.14 The Chinese Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.15 The Brazilian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.16 The Russian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 4.17 The Indian Multiple Myeloma Drug Market: Revenue Forecast ($m), 2013-2023 Figure 5.1 The Leading Drugs for MM: Market Share (%), 2012 Figure 5.2 Leading Drugs for MM: Market Share (%), 2018 Figure 5.3 Leading MM Drugs: Market Share (%), 2023 Figure 5.4 Revlimid: Drivers and Restraints, 2013-2023 Figure 5.5 Revlimid: Revenue Forecast ($m), 2013-2023 Figure 5.6 Velcade: Driving and Restraining Forces, 2013-2023 Figure 5.7 Velcade: Revenue Forecast ($m), 2013-2023 Figure 5.8 Thalomid: Driving and Restraining Forces, 2013-2023 Figure 5.9 Thalomid: Revenue Forecast ($m), 2013-2023 Figure 5.10 Zometa: Driving and Restraining Forces, 2013-2023 Figure 5.11 Zometa: Revenue Forecast ($m), 2013-2023 Figure 5.12 Kyprolis: Driving and Restraining Factors, 2013-2023 Figure 5.13 Kyprolis: Revenue Forecast ($m), 2013-2023 Figure 5.14 Pomalyst: Driving and Restraining Forces, 2013-2023 Figure 5.15 Pomalyst: Revenue Forecast ($m), 2013-2023 Figure 5.16 Elotuzumab: Driving and Restraining Forces, 2013-2023 Figure 5.17 Elotuzumab: Revenue Forecast ($m), 2013-2023 Figure 5.18 MLN9708: Driving and Restraining Factors, 2013-2023 Figure 5.19 MLN9708: Revenue Forecast ($m), 2013-2023 Figure 5.20 Panobinostat: Driving and Restraining Forces, 2013-2023 Figure 5.21 Panobinostat: Revenue Forecast ($m), 2013-2023 Figure 5.22 Aplidin: Driving and Restraining Forces, 2013-2023 Figure 5.23 Aplidin: Revenue Forecast ($m), 2013-2023
www.visiongain.com
Contents
Figure 6.1 Breakdown of Small Molecule Drug Pipeline by Development Phase (%), 2013 Figure 6.2 Breakdown of Biologic Drug Pipeline by Development Phase (%), 2013 Figure 7.1 Leading Companies in the MM Drug Market: Market Share (%), 2012 Figure 10.1 The World MM Drug Treatment Market: Breakdown of Revenue ($m) by Therapeutic Class, 2012 Figure 10.2 The MM Drug Treatment Market: Revenue ($m) by Country, 2012, 2018 and 2023 Figure 10.3 Leading Drugs of the Multiple Myeloma Market: Comparison of Revenue ($m), 2012, 2018 and 2023
www.visiongain.com
Contents
Companies and Organisations Mentioned in the Report
AB Science Abbott Laboratories AbbVie Abramsom Cancer Centre Abraxis Actavis Allos Therapeutics Amgen Anthrogenesis Arno Therapeutics Array Biopharma Astellas Astex Pharmaceuticals AstraZeneca Bayer Biogen Idec Biotest Pharmaceuticals Bristol-Myers Squibb Broad Institute Cancer Research UK Celanese Celgene Cell Genesys Celldex Therapeutics Cephalon Constellation Pharmaceuticals Cougar Biotechnology Dana-Farber Cancer Institute
www.visiongain.com
Contents
Dr. Reddys Laboratories Eli Lilly Emcure Pharmaceuticals Entremed EntreMed Epizyme European Medicines Agency (EMA) Food and Drug Administration (FDA) Galapagos Genentech Genmab Geron Corporation GlaxoSmithKline (GSK) Gliknik Gloucester Pharmaceuticals Harvard Medical School Hospira Human Genome Sciences Immune System Therapeutics ImmunoGen Immunomedics Janssen Biotech Jerome Lipper Centre for Multiple Myeloma Johnson & Johnson Karyopharm Therapeutics Kyowa Hakko Kirin Pharma Kyowa Hakko Kirin Pharma Leukosite Lipomed MD Anderson Cancer Centre
www.visiongain.com
Contents
Merck & Co. Millennium Pharmaceuticals MorphoSys Multiple Myeloma Research Consortium Multiple Myeloma Research Foundation Mylan Myogenics/ ProScript Natco Pharma National Institute for Health and Care Excellence (NICE) Nereus Pharmaceuticals Novartis Oncolytics OncoPep Oncopeptides Oncovir Onyx Pharmaceuticals Otsuka America Pharmaceutical PDL BioPharma Pfizer Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmacyclics PharmaMar Pharmion Pharmion Roche Rockefeller University Seattle Genetics Senesco Technologies Signal Pharmaceuticals Sun Pharma Global
www.visiongain.com
Contents
Synta Pharmaceuticals Takeda Teva Pharmaceuticals The World Health Organization (WHO) Threshold Pharmaceuticals Translational Genomics Research Institute University of Arkansas University of Illinois US National Comprehensive Cancer Network Watson Pharmaceuticals
www.visiongain.com
Restraints
Revlimid is an improved version of Thalomid, limiting the commercial scope for the older product. The recent approval of the next immunomodulator, Pomalyst, will further reduce demand for Thalomid. Generic versions of the product are an option for a company who sees it as commercially viable. Source: visiongain 2013
www.visiongain.com
Page 85
www.visiongain.com
Page 86